Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Tumors Refractory To Standard Therapy Clear all
Completed Phase 1 Interventional

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

NCT00741234
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
Interventions
SB939, Azacitidine
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Jul 24, 2026, 10:55 AM EDT
Active, not recruiting Phase 1 Interventional

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

NCT02112565
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
RNR inhibitor COH29, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00027898
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, carboplatin, etoposide, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Jul 24, 2026, 10:55 AM EDT
Not listed Phase 1 Interventional

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

NCT05989724
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Interventions
SON-DP
Drug
Lead sponsor
Qurgen Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

NCT04686383
View directory record Official record
Conditions
Resistant or Refractory Solid Tumors
Interventions
CAL056 mesylate
Drug
Lead sponsor
Calgent Biotechnology Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

NCT01209143
View directory record Official record
Conditions
Solid Cancers
Interventions
Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01924689
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
Clostridium novyi-NT spores
Biological
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
St Louis, Missouri • New York, New York • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

NCT00839631
View directory record Official record
Conditions
Solid Tumors
Interventions
EC D-3263 HCl
Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Jul 24, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation for Metastatic Solid Tumors

NCT00001880
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
methotrexate, Cyclosporin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jul 24, 2026, 10:55 AM EDT
Terminated Phase 1 Interventional Results available

PTX-35 in Patients With Advanced Solid Tumors

NCT04430348
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
PTX-35
Drug
Lead sponsor
Pelican Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Portland, Oregon • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

NCT00416624
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 24, 2026, 10:55 AM EDT
Terminated Phase 1 Interventional

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01118819
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
Clostridium novyi-NT spores
Biological
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jul 24, 2026, 10:55 AM EDT
Terminated Phase 1 Interventional

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

NCT00089089
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
decitabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

NCT04116710
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
HS-110 (viagenpumatucel-L), HS-130
Biological
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jul 24, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

NCT01346358
View directory record Official record
Conditions
Neoplasms
Interventions
IMC-CS4
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 24, 2026, 10:55 AM EDT